Spleen-targeted mRNA vaccine doped with metal ion adjuvant and preparation method and application of spleen-targeted mRNA vaccine

By introducing targeted functional lipids and Mn2+ adjuvants in mRNA-LNP vaccines, targeted delivery of the spleen is achieved and cGAS-STING signaling pathway is activated, which solves the problems of low delivery efficiency and high side effects of existing mRNA tumor vaccines, and significantly The anti-tumor treatment effect and overall survival of mice were improved.

CN118949071AActive Publication Date: 2024-11-15INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Patent Information

Application Number
CN202411056134.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Existing mRNA tumor vaccines have problems with low efficiency and high side effects in delivering and activating immune responses, especially in therapeutic anti-tumor applications, which are difficult to achieve effective spleen targeting and immune cell activation.

Method used

The spleen-targeted mRNA-LNP vaccine with doped metal adjuvant Mn2+ is used to introduce targeted functional lipids and anionic lipids, and combine Mn2+ adjuvant to improve the delivery efficiency of mRNA and Mn2+ to spleen antigen presenting cells and activate cGAS -STING signaling pathway, enhances immune response.

Benefits of technology

It significantly improved the anti-tumor treatment effect of mRNA vaccine, reduced the toxic side effects caused by high dose administration, achieved the activation of strong immune response and long-term memory T cell production at low doses, and extended the total mice Survival period.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976483560000121
    Figure BDA0004976483560000121
  • Figure BDA0004976483560000211
    Figure BDA0004976483560000211
  • Figure HDA0004976483570000011
    Figure HDA0004976483570000011
Patent Text Reader

Abstract

The invention discloses a spleen targeted mRNA (messenger ribonucleic acid) vaccine doped with a metal ion adjuvant. The mRNA vaccine comprises spleen targeted lipid nanoparticles entrapped with mRNA and a metal ion adjuvant, the spleen targeted lipid nanoparticles entrapped with mRNA comprise spleen targeted lipid nanoparticles and mRNA, wherein the spleen targeted lipid nanoparticles entrapped with mRNA comprise spleen targeted lipid nanoparticles and mRNA; the spleen targeting lipid nanoparticles comprise the following raw materials: ionized lipid, auxiliary phospholipid, cholesterol, a polyethylene glycol-lipid conjugate and targeting functional lipid (anionic lipid). The anionic lipid is introduced into a traditional LNP component to serve as a fifth component, spleen lymphatic organ targeting is effectively achieved, meanwhile, the adjuvant Mn < 2 + > can be more efficiently entrapped through electrostatic adsorption between the anionic lipid and the adjuvant Mn < 2 + >, and therefore an antigen and the adjuvant are delivered to antigen presenting cells in the spleen at the same time; while the activation immune efficiency of Mn < 2 + > at a specific part is improved, the effectiveness of the mRNA vaccine is enhanced, and the off-target toxicity is reduced, so that the aims of treating and preventing tumors are fulfilled.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of nanomedicine, and specifically relates to a spleen-targeted mRNA vaccine doped with a metal ion adjuvant, a preparation method thereof, and an application thereof in tumor immunotherapy. Background Art

[0002] The success of mRNA vaccines in combating the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infectious disease highlights the application value of this technology in responding to sudden infectious diseases. In recent years, the research and development of mRNA anti-tumor vaccines has become increasingly eye-catching. Due to its advantages such as short research and development cycle and personalized design, a number of preclinical and clinical trials have been carried out, showing positive therapeutic effects in melanoma, non-small cell lung cancer and colorectal tumors, bringing significant clinical benefits. Despite this, there is still much room for improvement in the effectiveness of mRNA tumor vaccines. The key points are: 1) how to accurately deliver mRNA to antigen-presenting cells to activate specific immune responses; 2) how to improve antigen presentation efficiency and immune activation ability.

[0003] Since mRNA is easily degraded and difficult to pass through the cell membrane freely, it is particularly important to develop a suitable delivery vehicle. Lipid nanoparticles (LNP) have been successfully used in the development of mRNA vaccines as a safe and effective delivery vehicle, the most representative of which is the new crown mRNA-LNP vaccine approved by the FDA. In addition, the clinical results of a number of anti-tumor mRNA vaccines are also relatively positive. Therapeutic anti-tumor mRNA vaccines deliver mRNA containing encoded antigen proteins to antigen-presenting cells, and translate them into corresponding antigen proteins, thereby inducing the body to produce specific T cell responses and achieve the effect of killing tumors. Therefore, targeting immune organs and antigen-presenting cells is an effective way to improve the efficacy of mRNA vaccines. The patent with publication number CN112996519A discloses a composition and method for organ-specific delivery of nucleic acids. The addition of selective organ-targeted lipids to the conventional LNP dosage form can achieve the delivery of mRNA to a variety of extrahepatic organ tissues. The spleen is the largest peripheral immune organ in the body. The antigen-presenting cells in the spleen are adjacent to B cells and T cells, providing an ideal microenvironment for efficient initiation of humoral and cellular immunity. Therefore, the development of spleen-targeted mRNA-LNP vaccines is expected to enhance antigen presentation by antigen-presenting cells and T cell immune activation, thereby enhancing the anti-tumor immune activity of mRNA-LNP vaccines.

[0004] Unlike vaccines for preventing infectious diseases, therapeutic anti-tumor mRNA vaccines need to activate a stronger immune response in the body to achieve the desired therapeutic effect, which often requires higher doses and multiple administrations to achieve, thus increasing potential safety risks and immune tolerance risks. The combined use of metal immune adjuvants is expected to solve the subsequent adverse reactions caused by insufficient immune activation. A large number of studies have shown that activating the stimulator of interferon genes (STING) signaling pathway can induce type I interferon (IFN) secretion, thereby enhancing antigen presentation and anti-tumor immunity. In the cGAS-STING signaling pathway, the DNA receptor cGAS recognizes abnormally exposed dsDNA in the cytoplasm and catalyzes GTP and ATP to form the secondary messenger 2'3'-cyclic-GMP-AMP (cGAMP). cGAMP then binds to the receptor protein STING homodimer located in the endoplasmic reticulum membrane, initiates conformational changes in the STING dimer and causes activation. Recent studies have shown that divalent manganese ions (Mn 2+ ) can directly activate cGAS, significantly enhance the binding affinity of cGAMP and STING and induce the secretion of type I IFN, thereby improving the body's antiviral infection and immune regulation. Therefore, it is necessary to design a method that can effectively encapsulate the adjuvant Mn 2+ The mRNA-LNP vaccine delivered to immune cells can improve the immunogenicity of the mRNA-LNP vaccine and reduce the side effects of the synergistic immune adjuvant. 2+ The research on the use of adjuvants for tumor immunotherapy has not yet been developed. Summary of the invention

[0005] In order to improve the efficacy of anti-tumor mRNA vaccines and significantly reduce the toxic side effects caused by non-specific delivery and high-dose administration, the present invention adopts an "All-in-One" strategy to construct a metal adjuvant Mn 2+ The spleen-targeted mRNA-LNP vaccine was developed. This nanosystem introduces targeted functional lipids into traditional LNPs and co-delivers Mn 2+ Adjuvants and mRNA promote the expression of antigens and Mn 2+ Adjuvants are also delivered to antigen-presenting cells in the spleen, helping to increase Mn 2+ It can activate immunity efficiently at specific sites and have good biosafety, promote the maturation of antigen-presenting cells, and induce antigen-specific immune responses, thereby improving the effectiveness of mRNA vaccines and achieving the purpose of tumor treatment and prevention.

[0006] The above-mentioned object of the present invention is achieved by the following technical solutions:

[0007] In a first aspect, the present invention provides a spleen-targeted lipid nanoparticle encapsulating mRNA.

[0008] The spleen-targeted lipid nanoparticles encapsulating mRNA provided by the present invention include spleen-targeted lipid nanoparticles and mRNA; the spleen-targeted lipid nanoparticles are made of raw materials including ionizable lipids, auxiliary phospholipids, steroid lipids, polyethylene glycol-lipid conjugates and targeted functional lipids;

[0009] Wherein, the targeted functional lipid is an anionic lipid, and the anionic lipid is selected from phospholipids containing at least one of the following anionic heads: phosphatidylglycerol (PG), phosphatidylserine (PS) and phosphatidic acid (PA).

[0010] Furthermore, the phospholipid containing a phosphatidylglycerol (PG) anion head is preferably selected from at least one of the following: DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-RAC-(1-glycerol) sodium salt), DOPG (1,2-dioleoyl-sn-glycero-3-phospho-RAC-glycerol sodium salt), DSPG (1,2-distearoyl-tin-glycero-3-phospho-rac-(1-glycerol) sodium salt), DLPG (1,2-dilauroyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt), DPPG (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt), POPG (1-palmitoyl-2-oleyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt), etc. One or more thereof; preferably DOPG.

[0011] Furthermore, the phospholipid containing a phosphatidylserine (PS) anion head is preferably selected from at least one of the following: DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine sodium salt), DSPS (1,2-distearoyl-sn-glycero-3-phospho-L-serine sodium salt), 16:0-18:2PS (1-palmitoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine sodium salt), 18:0-18:1PS (1-stearoyl-2-oleoyl-sn-glycero-3-phospho-L-serine sodium salt), 18:0-18:2PS (1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine sodium salt) and POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine sodium salt), etc. One or more thereof; preferably DOPS.

[0012] Furthermore, the phospholipid containing a phosphatidic acid (PA) anion head is selected from at least one of the following: 17:0PA (1,2-heptadecanoyl-sn-glycerol-3-phosphate sodium salt), 18PA (1,2-dioleoyl-sn-glycerol-3-phosphate sodium salt), DMPA (1,2-dimyristoyl-sn-glycerol-3-phosphate sodium salt), DLPA (1,2-dilauroyl-sn-glycerol-3-phosphate sodium salt), DSPA (1,2-distearoyl-sn-glycerol-3-phosphate sodium salt), POPA (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate sodium salt), etc. One or more; preferably 18PA.

[0013] Preferably, the molar percentage of the anionic lipid in the raw material (total lipid) is 1-50%, preferably 5-30%, more preferably 10-20%, and more preferably 15%.

[0014] Preferably, the ionizable lipids include but are not limited to: SM-102 (heptadecan-9-yl-8-((2-hydroxyethyl)(6-oxo-6-((undecanyloxy)hexyl)aminocaprylate)), ALC-0315 (((4-hydroxybutyl)azepinediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)), cKK-E12 (3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione), DLi n-MC3-DMA (4-(N,N-dimethylamino)butyric acid (dilinoleyl) methyl ester), DLin-KC2-DMA (N,N-dimethyl-2,2-di-(9Z,12Z)-9,12-octadecen-1-yl-1,3-dioxolane-4-ethylamine), and 306Oi10 (tetrakis(8-methylnonyl) 3,3',3",3"'-(((methylazadialkyl)bis(propane-3,1-diyl))bis(azatriyl))tetrapropionate);

[0015] Preferably, the auxiliary phospholipids include but are not limited to: DSPC (1,2-distearoyl-sn-glyceryl-3-phosphatidylcholine), DPPC (1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylcholine), DOPC (1,2-dioleoyl-sn-glyceryl-3-phosphatidylcholine), POPC (2-oleoyl-1-palmitoyl-sn-glyceryl-3-phosphatidylcholine), DOPE (1,2-dioleoyl-sn-glyceryl-3-phosphatidylethanolamine), POPE (1-palmitoyl-2-oleoyl-phosphatidylethanolamine), DSPE (1,2-distearoyl-sn-glyceryl-3-phosphatidylethanolamine) and DPPE (1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylethanolamine);

[0016] Preferably, the steroidal lipids include, but are not limited to, cholesterol, cholestanol, 7α-hydroxycholesterol, β-sitosterol, 7β-hydroxycholesterol, cholestanone and cholestenone;

[0017] Preferably, the polyethylene glycol-lipid conjugate includes but is not limited to: DMG-PEG2000 (1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000), DSG-PEG2000 (1,2-distearoyl-rac-glycerol-3-methoxypolyethylene glycol 2000), DSPE-mPEG2000 (distearoylphosphatidyl acetamide-methoxypolyethylene glycol 2000) and ALC-0159 (methoxypolyethylene glycol ditetradecyl acetamide);

[0018] Preferably, the molar percentage of the ionizable lipids in the raw material (total lipids) is 20-60%, preferably 30-50%, more preferably 39.35%.

[0019] Preferably, the molar percentage of the auxiliary phospholipids in the raw material (total lipids) is 1-20%, preferably 2-10%, and more preferably 7.99%.

[0020] Preferably, the molar percentage of the steroidal lipids in the raw material (total lipids) is 20-60%, preferably 30-50%, and more preferably 36.29%.

[0021] Preferably, the molar percentage of the polyethylene glycol-lipid conjugate is 0.1-10%, preferably 0.5-5%, and more preferably 1.36%.

[0022] Preferably, the mass ratio of the total mass of lipid molecules forming the spleen-targeted lipid nanoparticles to the nucleic acid in the mRNA-encapsulated spleen-targeted lipid nanoparticles is (10-50):1, specifically 40:1.

[0023] Preferably, the particle size of the spleen-targeted lipid nanoparticles encapsulating mRNA is 140 to 200 nm, and the polydispersity index is 0.1 to 0.2.

[0024] Preferably, the spleen-targeted LNP that best activates the immune response includes any one of 18PALNP, DOPG LNP, and DOPS LNP, and more preferably DOPS LNP.

[0025] In a second aspect, the present invention provides a method for preparing the spleen-targeted lipid nanoparticles encapsulating mRNA as described in the first aspect.

[0026] The method for preparing the spleen-targeted lipid nanoparticles encapsulating mRNA comprises the following steps:

[0027] Step (A1): dissolving an ionizable cationic lipid, an auxiliary phospholipid, cholesterol, a polyethylene glycol-lipid conjugate and a targeting functional lipid in an organic solvent at a specific molar percentage to obtain a lipid organic phase;

[0028] Step (A2): dissolving the mRNA in an appropriate buffer solution to obtain an mRNA solution;

[0029] Step (A3): The lipid organic phase in step (A1) and the mRNA solution in step (A2) are mixed and incubated to obtain a solution of spleen-targeted lipid nanoparticles encapsulating mRNA.

[0030] Preferably, the organic solvent includes any one of methanol, ethanol, propanol, tetrahydrofuran, and diethyl ether, or a combination of at least two of them.

[0031] Preferably, the pH value of the buffer solution is 2.0-8.0, more preferably the pH value is 4.0. Further, the buffer solution is a citrate buffer or an acetate buffer, more preferably a citrate buffer.

[0032] Preferably, the mass ratio of the total mass of lipid molecules in the lipid organic phase to the mass ratio of mRNA in the mRNA solution is (10-50):1, and the more preferred mass ratio is 40:1.

[0033] Preferably, the volume ratio of the lipid organic phase to the mRNA solution is 1:(1-5), and a more preferred volume ratio is 1:3.

[0034] Preferably, the incubation condition is static incubation at room temperature for 10-15 minutes.

[0035] The method further comprises the step of dialyzing the mRNA-encapsulated spleen-targeted lipid nanoparticle solution obtained in step (A3).

[0036] The dialysis was performed in Pur-A-Lyzer Maxi 3500 dialysis tubing against a large volume of 0.01 M PBS for at least 2 hours to remove ethanol.

[0037] The present invention optimizes the molar ratio of anionic lipids in LNP to achieve higher spleen targeting efficiency. The spleen-targeted LNP involved in the present invention can be effectively taken up by antigen presenting cells (APCs) both in vitro and in vivo to activate strong humoral immunity and antigen-specific T cell responses, and enhance the delivery efficiency and effectiveness of mRNA vaccines.

[0038] In a third aspect, the present invention provides a spleen-targeted lipid nanoparticle encapsulating mRNA and adjuvant metal ions.

[0039] The spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions provided by the present invention include the spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions described in the first aspect of the present invention; the metal ions include but are not limited to one or more of metal ions such as manganese ions, copper ions, zinc ions, aluminum ions, iron ions, ferrous ions and cobalt ions, preferably manganese ions.

[0040] When the adjuvant metal ion is an adjuvant metal ion, the anionic lipid in the spleen-targeted lipid nanoparticles containing mRNA is in contact with the adjuvant metal ion (such as Mn 2+ ) is 1:(0-10), more preferably 1:(1-5), and most preferably 1:1.

[0041] Preferably, the adjuvant metal ion is a divalent manganese salt including any one of manganese chloride, manganese nitrate or manganese sulfate, preferably manganese chloride.

[0042] In a fourth aspect, the present invention provides a method for preparing the spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions according to the third aspect of the present invention.

[0043] The method for preparing spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions of the present invention comprises the following steps:

[0044] Step (B1): dissolving ionizable cationic lipids, auxiliary phospholipids, cholesterol, polyethylene glycol-lipid conjugates and targeted functional lipids in an organic solvent at a specific molar percentage to obtain a lipid organic phase;

[0045] Step (B2): dissolving the adjuvant metal ion and mRNA with an appropriate buffer solution to obtain an aqueous solution;

[0046] Step (B3): The lipid organic phase in step (B1) and the aqueous phase solution in step (B2) are mixed and incubated to obtain a solution of spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions.

[0047] Preferably, the organic solvent includes any one of methanol, ethanol, propanol, tetrahydrofuran, and diethyl ether, or a combination of at least two of them.

[0048] Preferably, the pH value of the buffer solution is 2.0-8.0, more preferably the pH value is 4.0. Further, the buffer solution is a citrate buffer or an acetate buffer, more preferably a citrate buffer.

[0049] Preferably, the mass ratio of anionic lipid to adjuvant metal ion in the lipid organic phase is 1:(0-10), more preferably 1:(1-5), and most preferably 1:1.

[0050] Preferably, the mass ratio of the total mass of lipid molecules in the lipid organic phase to the mass ratio of mRNA in the mRNA solution is (10-50):1, and the more preferred mass ratio is 40:1.

[0051] Preferably, the volume ratio of the lipid organic phase to the mRNA solution is 1:(1-5), and a more preferred volume ratio is 1:3.

[0052] Preferably, the incubation condition is static incubation at room temperature for 10-15 minutes.

[0053] The method further comprises the step of dialyzing the spleen-targeted lipid nanoparticle solution encapsulating mRNA and adjuvant metal ions obtained in step (B3).

[0054] The dialysis was performed in Pur-A-Lyzer Maxi 3500 dialysis tubing using a large volume of 0.01 M PBS for at least 2 hours to remove the unencapsulated adjuvant Mn. 2+ .

[0055] The present invention combines anionic lipids with adjuvant metal ions (such as Mn 2+ ) between the electrostatic adsorption to achieve efficient encapsulation of adjuvant metal ions by LNP, combined with the method described in the second aspect, the anionic lipid is preferably DOPS, the adjuvant Mn 2+ The mRNA encoding the tumor antigen was dissolved in citrate buffer and then quickly mixed into the lipid solution. The above solution was incubated at room temperature for 10-15 minutes, and the obtained solution was dialyzed for at least 2 hours to remove the unencapsulated adjuvant Mn. 2+ Finally, the co-encapsulated mRNA and metal ion adjuvant Mn 2+ DOPS LNP, when the adjuvant metal ion is Mn 2+ , abbreviated as Mn@mRNA-LNP.

[0056] In a preferred embodiment of the present invention, the anionic lipid DOPS and the adjuvant Mn 2+ The mass ratio of Mn@mRNA-LNP was 1:(0-10). Under this ratio, LNP achieved high encapsulation efficiency, uniform dispersion and improved mRNA transfection efficiency. The optimized Mn@mRNA-LNP increased the cGAS-STING pathway in antigen-presenting cells, promoted the activation of antigen-presenting cells, and further triggered a stronger OVA-specific CTL response than DOPS LNP.

[0057] In a fifth aspect, the present invention provides a use of spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions in the preparation of vaccines for tumor immunotherapy.

[0058] The tumor includes, but is not limited to, one or more of melanoma, colon cancer, liver cancer, breast cancer, glioma, ovarian cancer, gastric cancer, prostate cancer and lung cancer.

[0059] In the present invention, doping with Mn 2+ The adjuvanted spleen-targeted mRNA-LNP vaccine effectively inhibited the progression of established and post-surgery B16-OVA tumors after vaccination and prolonged the overall survival of mice.

[0060] In a sixth aspect, the present invention provides a pharmaceutical composition for treating tumors.

[0061] The pharmaceutical composition for treating tumors provided by the present invention comprises the packaged mRNA as described in the third aspect of the present invention and an adjuvant metal ion (such as Mn 2+ )'s spleen-targeted lipid nanoparticles and immune checkpoint inhibitors.

[0062] Preferably, the immune checkpoint inhibitors include but are not limited to: PD-1 antibody, PD-L1 antibody or CTLA-4 antibody, etc.

[0063] In the seventh aspect, the present invention also provides a combined anti-cancer method based on spleen-targeted mRNA-LNP vaccine doped with metal ion adjuvant.

[0064] The method comprises administering the pharmaceutical composition for treating tumors described in the sixth aspect above to a subject in need thereof.

[0065] In the present invention, the mRNA is any mRNA molecule that can encode one or more tumor antigens. The example shows that the tumor antigen mRNA can encode seven MC38 neoantigens, which have been confirmed in previous studies to be effectively presented by MHC I and induce CD8+ T cell responses.

[0066] In the present invention, by doping Mn 2+ The adjuvanted spleen-targeted mRNA-LNP vaccine delivered mRNA encoding MC38 neoantigens to prepare the neoantigen mRNA-LNP vaccine. The neoantigen mRNA-LNP vaccine effectively alleviated the progression of MC38 tumors. Notably, the combination of anti-PD-1 antibodies further increased the percentage of complete tumor regression and prolonged the overall survival of mice.

[0067] Compared with the prior art, the present invention has the following beneficial effects:

[0068] (1) The preparation method of the present invention is simple, and the required equipment is conventional equipment, which can realize large-scale production and has good clinical transformation prospects.

[0069] (2) The present invention uses lipid nanoparticles as mRNA delivery carriers, which have good safety and stability. The present invention can achieve targeted delivery to the spleen organ without excessive modification of the lipid nanoparticles by introducing the anionic lipid DOPS, and can also deliver to antigen presenting cells in the spleen organ, significantly improving the bioavailability of the mRNA vaccine. Moreover, DOPS LNP can induce Th1 and Th2 responses at the same time, which helps to promote strong cytotoxic T lymphocyte responses and humoral immune responses.

[0070] (3) The present invention co-delivers manganese adjuvant and mRNA encoding tumor antigens through DOPS LNP with spleen targeting and immune activation capabilities. The efficient encapsulation of manganese ions is achieved through electrostatic adsorption with anionic lipid DOPS. The optimized Mn@mRNA-LNP effectively encapsulates Mn 2+ The adjuvant is delivered to antigen-presenting cells and promotes the expression of mRNA encoding anti-tumor antigens, achieving more efficient activation of the STING signaling pathway at a lower dose, upregulating IRF-7 and IFN-β expression in a short period of time, promoting the activation of DC cells and inducing the production of cytotoxic T cells, ultimately effectively inhibiting the progression of established and postoperative B16-OVA tumors.

[0071] (4) The present invention uses spleen-targeted LNP to simultaneously encapsulate tumor antigen mRNA and Mn 2+ The Mn@mRNA-LNP vaccine prepared by (All-in-One) showed better anti-tumor therapeutic effects in multiple mouse models, and the preparation can induce the production of long-term memory T cells, which helps prevent tumor recurrence.

[0072] (5) The present invention combines the spleen-targeted mRNA tumor vaccine based on doped manganese ions with anti-PD-1 for anti-tumor treatment. Although monotherapy with anti-PD-1 or Mn@Neo-mRNA-LNP can effectively alleviate tumor progression, the complete tumor regression rate is 0.0%. The combined treatment group of Mn@Neo-mRNA-LNP and anti-PD-1 antibody increased the percentage of complete tumor regression to 25.0%, significantly inhibiting tumor progression and prolonging the overall survival of mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 This is a schematic diagram of the present invention's "A spleen-targeted mRNA vaccine preparation technology and application doped with metal ion adjuvant".

[0074] Figure 2 To characterize the physicochemical properties of spleen-targeted LNP prepared in Example 2. Figure 2 A to Figure 2C are the results of evaluating the particle size, polydispersity index and particle size change of 18PA / DOPG / DOPS LNPs containing different ratios in PBS within seven days.

[0075] Figure 3 These are fluorescence images of major organs collected 6 hours after the delivery of 0.1 mg / kg Lu cmRNA by 10%, 15%, and 20% 18PA / DOPG / DOPS LNPs in Example 3.

[0076] Figure 4 This is the statistical result of the fluorescence intensity of the spleen organ in Example 3.

[0077] Figure 5 This is a statistical graph evaluating the spleen targeting efficiency of 18PA / DOPG / DOPS LNPs containing 10%, 15% and 20% in Example 3 based on the fluorescence intensity of the liver, spleen and lung organs.

[0078] Figure 6 This is the transfection status of dendritic cells in Example 4 after incubation with 18PA / DOPG / DOPS LNP for 24 hours.

[0079] Figure 7 This is the activation and antigen presentation of dendritic cells after 18PA / DOPG / DOPS LNP acts on them in Example 5, wherein: Figure 7 A is a flow cytometric map showing the expression of dendritic cells CD86 and SIINFEKL-H-2Kb. Figure 7 B and 7C are the quantitative analysis results of flow cytometry.

[0080] Figure 8 In Example 6, Cre mRNA was delivered by 18PA / DOPG / DOPS LNP to achieve gene editing of spleen tissue in Ai9 mice; Figure 8 A is a schematic diagram showing that the delivery of Cre mRNA preparation activated tdTom expression in Ai9 mice. Figure 8 B is the fluorescence of spleen detected 48h after Ai9 mice were injected with 18PA / DOPG / DOPS LNP (0.5mg / kg Cre mRNA) through tail vein. Figure 8 C is the statistical result of the fluorescence intensity of spleen organs in each group.

[0081] Fig. 9 The percentage of tdTom+ cells in specific cell subtypes (B, T, DC and MΦ) in the spleen was determined by flow cytometry in Example 6.

[0082] Fig.10Serum from mice immunized with 18PA / DOPG / DOPS LNP was collected in Example 7, and the OVA-specific IgG1 ( Fig.10 A) and IgG2c( Fig.10 B) Antibody titers.

[0083] Fig.11 The percentage of OVA-specific T cells in the spleen determined by flow cytometry in Example 8; Fig.11 A is a representative flow cytometric profile of H-2kb / SIINFEKL tetramer staining of CD8+ T cells in the spleen. Fig.11 B is the quantitative analysis result of OVA-specific T cells.

[0084] Fig.12 The in vivo cytotoxic killing experiment in Example 9 was used to evaluate the antigen-specific CTL response induced by 18PA / DOPG / DOPS LNP; Fig.12 A Schematic diagram of the determination of OVA antigen-specific CTL responses by the CFSE method, and representative flow cytometric profiles of OVA antigen-specific killing in the spleen of immunized mice ( Fig.12 B) and quantitative percentage ( Fig.12 C).

[0085] Fig.13 To prepare and characterize different Mn@mRNA-LNP preparations in Example 10; the particle sizes of different Mn@mRNA-LNP preparations were detected by DLS ( Fig.13 A), polydispersity index ( Fig.13 B) and zeta potential ( Fig.13 C).

[0086] Fig.14 In order to determine the Mn content of adjuvants with different masses by Ribogreen method and ICP-MS in Example 10 2+ Mn@mRNA-LNP(DOPS / Mn 2+ ,w / w) of mRNA( Fig.14 A) and adjuvant Mn 2+ Packaging efficiency ( Fig.14 B).

[0087] Fig.15 In order to determine the relationship between DOPS and different metal ion adjuvants (Cu 2+ 、Zn 2+ and Al 3 + ) Encapsulation efficiency of metal ion adjuvants at a mass ratio of 1:1.

[0088] Fig.16 The A549 cells in Example 12 were treated with adjuvants containing different masses of Mn 2+ Cell viability after 24 h of incubation with Mn@Luc-mRNA-LNP preparation ( Fig.16 A) and transfection status ( Fig.16 B).

[0089] Fig.17 In Example 13, the adjuvant Mn containing different masses 2+ Mn@mRNA-LNP(DOPS / Mn 2+ Fluorescence images of major organs collected 6 hours after delivery of 0.1 mg / kg Luc mRNA (w / w) Fig.17 A) and the statistical results of fluorescence intensity of major organs ( Fig.17 B).

[0090] Fig.18 The fluorescence intensity of liver, spleen and lung organs in Example 13 was used to evaluate the effect of different adjuvant Mn 2+ Statistical graph of the spleen targeting efficiency of Mn@Luc-mRNA-LNP.

[0091] Fig.19 The adjuvant Mn containing different masses in Example 14 2+ The activation of dendritic cells after the action of Mn@OVA-mRNA-LNP; Fig.19 A is the flow cytometry map. Fig.19 B shows the expression of CD86 on dendritic cells and the results of quantitative analysis.

[0092] Fig. 20 In Example 15, Mn@OVA-mRNA-LNP activated the STING signaling pathway by encapsulating manganese adjuvant. DC2.4 cells were co-incubated with Mn@mRNA-LNP for 8 h or 24 h, and IRF-7 ( Fig. 20 A) and IFN-β mRNA ( Fig. 20 B) expression.

[0093] Fig.21 The activation and antigen cross-presentation of dendritic cells after Mn@OVA-mRNA-LNP acted on dendritic cells in Example 16. Flow cytometry showed that dendritic cell CD86 ( Fig.21 A) and CD40( Fig.21 B) Quantitative analysis results.

[0094] Fig. 22To evaluate the T cell response induced by Mn@OVA-mRNA-LNP in the spleen in Example 17, the secretion of CD8+IFN-γ+T in the spleen as well as the percentage of OVA-specific T cells were measured by flow cytometry; Fig. 22 A is a representative flow cytometric profile of CD8+IFN-γ+T and H-2kb / SIINFEKL tetramer staining of CD8+T cells in the spleen; Fig. 22 B and 22C are the quantitative analysis results of OVA-specific T cells.

[0095] Fig.23 The higher antigen-specific CTL response induced by Mn@OVA-mRNA-LNP in Example 17; Fig.23 A is a representative flow cytometric profile and quantitative percentage of CD8+T cell-specific killing in the spleen of immunized mice ( Fig.23 B).

[0096] Fig.24 Evaluation of the anti-tumor efficacy of Mn@OVA-mRNA-LNP in Example 18; Fig.24 A is a schematic diagram of the administration of Mn@OVA-mRNA-LNP; Fig.24 B is the average tumor growth curve of mice in each group.

[0097] Fig.25 This is a survival curve diagram of each group of mice in the B16-OVA treatment model in Example 18.

[0098] Fig.26 These are confocal images of CD4+T (red) and CD8+T (green) in tumor tissues of each group of mice on the 22nd day after receiving different treatments evaluated by immunofluorescence experiments in Example 18.

[0099] Fig. 27 The infiltration of effector T cells in the tumor of mice after receiving different treatments was analyzed by flow cytometry in Example 18; Fig. 27 A is the quantitative analysis result of CD45+CD3+ in tumor; Fig. 27 B is the quantitative analysis result of CD45+CD3+CD8+T cells in the tumor.

[0100] Fig.28 Evaluation of the anti-tumor recurrence effect of Mn@OVA-mRNA-LNP after surgery in Example 18; Fig.28 A is a schematic diagram of the construction of a mouse tumor recurrence model after surgery; Fig.28 B is the average tumor growth curve of mice in each group.

[0101] Fig.29This is a survival curve of each group of mice in the B16-OVA postoperative recurrence model in Example 18.

[0102] Fig.30 The representative flow cytometric profiles of effector T cells and effector memory T cells in the peripheral blood of mice after different treatments analyzed by flow cytometry in Example 18 ( Fig.30 A) and quantitative percentage ( Fig.30 B and Fig.30 C).

[0103] Fig.31 To evaluate the neoantigen-specific T cell response induced in vivo after immunization with the Neo-mRNA preparation in Example 19, representative flow cytometric profiles of CD8+IFN-γ+T secretion in spleen cells after different treatments were measured by flow cytometry ( Fig.31 A) and quantitative percentage ( Fig.31 B and 31C).

[0104] Fig.32 In Example 19, Mn@Neo-mRNA-LNP can induce neoantigen-specific CTL response; Fig.32 A is a representative flow cytometric profile and quantitative percentage of ADPGK / RESP1-specific killing in the spleen of immunized mice ( Fig.32 B and 32C).

[0105] Fig.33 Evaluation of the efficacy of Mn@Neo-mRNA-LNP against MC38 tumors in Example 20; Fig.33 A is a schematic diagram of drug administration of Mn@Neo-mRNA-LNP; Fig.33 B is the average tumor growth curve of mice in each group.

[0106] Fig.34 This is a survival curve diagram of each group of mice in the MC38 treatment model in Example 20. DETAILED DESCRIPTION

[0107] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0108] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0109] The materials used in the following examples are as follows:

[0110] (1) ALC-0315, DSPC and DMG-PEG (weight average molecular weight 2000) were purchased from Xiamen Sinopeg Company, cholesterol was purchased from Innochem Company, 18PA was purchased from Macklin Company, DOPG and MnCl 2 ·4H 2 O was purchased from Sigma-Aldrich and DOPS was purchased from Aladdin. Pur-A-Lyzer MIDIDialysis Kits (MWCO, 3.5 kDa) dialysis tubing was purchased from Sigma-Aldrich, ovalbumin and OVA 257–263 (SIINFEKL) was purchased from Invivogen. LPS and cell activity detection kit CCK-8 were purchased from Beyotime, luciferase assay system and passive lysis buffer (5X) were purchased from Promega. mRNA in vitro transcription kit was purchased from Thermo Fisher. Tumor tissue digestion fluid was purchased from Biogenous. Reps1 P45A With Adpgk R304M The peptides were synthesized by ChinaPeptides.

[0111] (2) CD11c-APC (Cat#: 17-0114-82, clone number: N418), CD-86-PE-Cy7 (Cat#: 25-0862-82, clone number: GL1), SIINFEKL / H-2Kb-PE (Cat#: 12-5743-81, clone number: 25-D1.16), CD45-FITC (Cat#: 11-0451-82, clone number: 30-F11), CD3-APC (Cat#: 17-0032-82, clone number: 17A2), B220-PE-Cy7 (Cat#: 25-0452-81, clone number: RA3-6B2), C D11b-PE-Cy7 (Cat#: 25-0112-81, clone: ​​M1 / 70), CD40-PE (Cat#: 12-0401-82, clone: ​​1C10), CD4-FITC (Cat#: 11-0041-82, clone: ​​GK1.5), CD8-PE (Cat#: 17-0032-82, clone: ​​17A2), CD44-PE-Cy7 (Cat#: 25-0441-82, clone: ​​IM7), and CD62L-PerCP-Cy5.5 (Cat#: 45-0621-82, clone: ​​MEL-14) were purchased from eBioscience TM CD8-FITC (Cat#: MA5-16759, Clone No.: KT15) and T-Select H-2Kb OVA Tetramer-SIINFEKL-PE (Cat#: TS-5001-1) were purchased from MBL.

[0112] Example 1: Synthesis of mRNA

[0113] The firefly luciferase (Luc), ovalbumin (OVA), cyclization recombinase (Cre) and neoantigen (Neo) mRNA involved in the present invention are all synthesized by in vitro transcription.

[0114] First, the coding sequence fragments of the above-mentioned proteins (as shown in SEQ ID.NO.1-4) are prepared by PCR program, and then these sequence fragments are cloned into a template plasmid vector with an optimized 5' (3') untranslated region and poly-A sequence, and the plasmid structure is determined by gene sequencing. After obtaining the plasmid containing the target gene fragment, it is cut into a linearized DNA template. Finally, the antigen-encoded mRNA is synthesized by in vitro transcription reagent. In order to reduce the immunogenicity of mRNA and enhance the stability and transcription efficiency of mRNA, the natural modified nucleoside N1-methyl pseudouridine triphosphate (m1ψTP) is introduced to replace uridine triphosphate (UTP), and CleanCap is used for co-transcription capping during in vitro transcription, and mRNA with Cap-1 structure can be directly obtained.

[0115] Amino acid sequence of Luc-mRNA coding sequence SEQ ID.NO.1:

[0116] MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKIL NVQKKLPIIQKIIIMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFLR SLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALI DKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAKKGGKIAV

[0117] The amino acid sequence of OVA-mRNA coding sequence is SEQ ID.NO.2:

[0118] MGSIGAASMEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSIEAQCGTSVNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAADQARELINSWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMYQIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVMEERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSP

[0119] Amino acid sequence of the Cre-mRNA coding sequence SEQ ID.NO.3:

[0120] MPKKKRKVANLLTVHQNLPALPVDATSDEVRKNLMDMFRDRQAFSEHTWKMLLSVCRSWAAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNAVSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLLRIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVADDPNNYLFCRVRKNGVAAPSATSQLSTRALEGIFEATHRLIYGAKDDSGQRYLAWSGHSARVGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGD

[0121] Amino acid sequence of the Neo-mRNA coding sequence SEQ ID.NO.4:

[0122] MDFTGSNGDPSSPYSLHYLSPTGVNEYKARDETAALLNSAVLGAAPLFVPPADSKLLSFMAPIDHTTMSDDARTELFRSGRVLELFRAAQLANDVVLQIMELCGATRDIDPSSSVLFEYMEKPDFSLFSPEAGQSLVISASIIVFNLLELEGDYRGIPVHLELASMTNMELMSSIVHQQVFPT

[0123] Example 2: Preparation and characterization of spleen-targeted LNPs

[0124] ALC-0315, DSPC, cholesterol, DMG-PEG and anionic lipids (18PA, DOPG or DOPS) are dissolved in ethanol at a specific molar percentage, wherein the anionic lipid DOPG can be directly dissolved in ethanol with other lipids, while the anionic lipids 18PA and DOPS need to be completely dissolved in anhydrous tetrahydrofuran before adding ethanol, so that the volume ratio of tetrahydrofuran to ethanol in the final 18PA and DOPS anionic lipid solutions is 2: 1. The mRNA encoding the antigen (specifically, Luc-mRNA, OVA-mRNA, Cre-mRNA or Neo-mRNA prepared in Example 1 above) is dissolved in 10mM citrate buffer (pH 4.0), and then the mRNA is quickly mixed into the lipid solution at a volume ratio of 3: 1 (mRNA: lipid, vol / vol), so that the final weight ratio reaches 40 / 1 (total lipid / mRNA, wt / wt). The above solution was then incubated at room temperature for 15 min, and the resulting solution was placed in a Pur-A-Lyzer Maxi 3500 dialysis tube and dialyzed with a large amount of 0.01 M PBS for at least 2 hours to remove ethanol, thereby obtaining spleen-targeted LNPs, which were placed at 4°C for later use. The spleen-targeted LNPs (18PA / DOPG / DOPS LNPs, referred to as 18PA, DOPG, and DOPS, respectively) were characterized by dynamic light scattering (DLS). Figure 2 A to Figure 2 C. It can be seen that the particle size range of the spleen-targeted LNP obtained in this embodiment is 140-200nm, and the polydispersity index is 0.1-0.3, indicating that the size of the above-mentioned nanoparticles is relatively uniform. At the same time, the above-mentioned LNP is placed at 4°C and its particle size change within seven days is evaluated. The experimental results show that the particle size of the above-mentioned LNP has no obvious change within seven days, indicating that it has good stability.

[0125] Table 1: Mole percentage of each component in spleen-targeted LNP

[0126]

[0127] Example 3: Screening of spleen-targeted LNPs

[0128] The 18PA / DOPG / DOPS LNPs containing different ratios prepared in Example 2 were injected into C57BL / 6 mice (18-20 g) via the tail vein with 0.1 mg / kg Luc mRNA, and 6 hours later, 100 μL D-luciferin potassium salt (30 mg / mL) was injected intraperitoneally, and the mice were imaged using the IVIS in vivo imaging system (Perkin Elmer). When the fluorescence intensity was stable, the mice were euthanized and the main organs (heart, liver, spleen, lungs and kidneys) of the mice were removed for imaging and the fluorescence intensity was analyzed using in vivo imaging software (Perkin Elmer).

[0129] Figure 3 is the fluorescence image of each organ, Figure 4 Statistics and comparison of the fluorescence intensity of each organ, Figure 5 The spleen targeting efficiency of 18PA / DOPG / DOPS LNPs containing different ratios was analyzed. The results showed that 18PA / DOPG / DOPS LNPs containing different percentages can be effectively and specifically targeted to the spleen organ, and the fluorescence intensity in the spleen is significantly higher than that of the traditional ALC-0315LNP (liver-targeted LNP). It was also found that the spleen targeting effect was optimal when the molar percentage of anionic lipids was 15%, so subsequent experiments used LNPs containing 15% anionic lipids.

[0130] Example 4: Transfection experiment of dendritic cells

[0131] Bone marrow-derived dendritic cells (BMDCs) were extracted from mice and cultured at 1×10 5 The cells were inoculated into a white 96-well plate at a density of 100 cells / mL, and then 50 μL of LNP containing 15% 18PA / DOPG / DOPS obtained in Example 2 was added, and 0.2 μg of Luc-mRNA was fixed in each well. After incubation for 24 hours, the supernatant was discarded, and 20 μL of 1X cell lysis buffer (Promega) was added to each well. After lysis for 20 minutes, 15 μL of the above lysate was taken to a white 96-well plate, and 50 μL of ONEGloTM luciferase substrate was added to each well to detect the expression of luciferase. The results are shown in FIG. Figure 6 As shown, pure Luc-mRNA cannot be effectively taken up by BMDCs, but using 15% 18PA / DOPG / DOPS LNP as an mRNA delivery vector can effectively enhance the delivery of Luc-mRNA to BMDCs, thereby improving the Luc-mRNA transfection efficiency.

[0132] Example 5: Dendritic cell activation and antigen presentation assay

[0133] In this example, OVA was used as the template antigen. The short peptide (SIINFEKL) at positions 257-264 of the OVA protein contains an antigen epitope that can be recognized by MHC I and is an antigen commonly used in research. OVA-mRNA (amino acid sequence is shown in SEQ ID. NO. 2) was synthesized as shown in Example 1. Therefore, immature BMDCs were cultured at 1×10 6 The cells were inoculated in a 24-well plate at a density of 10 cells / mL, and then LNPs containing 15% 18PA / DOPG / DOPS (containing 2.0 μg OVA-mRNA) and LPS (fixed at 2.0 μg per well) obtained in Example 2 were added and treated at 37°C for 48 hours. The cells were collected by centrifugation at 800 g for 5 minutes, and then the collected BMDCs were labeled by incubation with CD11c-APC, CD-86-PE-Cy7 and SIINFEKL / H-2Kb-PE fluorescent antibodies under dark conditions for 20 minutes. After washing the cells three times with 0.01 M PBS, the expression levels of CD11c+CD86+ and CD11c+SIINFEKL-H-2Kb+ on BMDCs were analyzed by flow cytometry. For specific flow cytometric profiles, see Figure 7 . Combined with the above Figure 7 From the results of A to 7C, it can be seen that the expression levels of the NC group (the NC group is the group without adding any substances) and the OVA-mRNA group are similar, indicating that they cannot upregulate the expression of CD86, while the 18PA / DOPG / DOPS LNP groups can upregulate the percentage of related protein CD86. At the same time, the 18PA / DOPG / DOPSLNP group can effectively increase the percentage of OVA peptide (SIINFEKL)-MHC-I complex compared with the control group, indicating that 18PA / DOPG / DOPS LNP can promote the maturation of BMDCs and the presentation of related antigens.

[0134] Example 6: Screening of cell subtypes transfected with LNP in spleen

[0135] In this example, the genetically engineered B6.Cg-Gt(ROSA)26Sor tm9(CAG-tdTomato)Hze / J mice (Ai9 mice) are used as model mice. They contain a stop box flanked by LoxP to prevent the expression of tdTom protein. Once the stop box is missing, tdTom protein can be effectively expressed. Therefore, it is often used to detect gene-edited cells. Delivery of Cre recombinase mRNA is one of the main ways to activate tdTom fluorescence in edited cells ( Figure 8A). In this example, in order to detect the ability of 18PA / DOPG / DOPS LNP to edit the spleen of mice, Cre mRNA preparation was prepared as described in Example 2 above, and tail vein injection (0.5 mg / kg Cre mRNA) was performed. Two days later, Ai9 mice were euthanized (n=3 per group), and spleen organs were imaged using the IVIS Lumina system (Perkin Elmer). The results are shown in Figure 8 As shown, 18PA / DOPG / DOPS LNP can effectively achieve editing of spleen organoids.

[0136] Subsequently, the cell subtypes transfected with LNP in the spleen were further detected, that is, the tdTom+ cells in the cell types in the spleen were detected, and the above spleens were collected, and the freshly collected spleens were added to a six-well plate containing 1 mL of RPMI 1640 complete medium, and the medium was blown evenly with a 1 mL sterile syringe until the medium was turbid, and the spleen was fully ground. The above medium containing spleen cells was passed through a 40 μm sieve to remove large pieces of tissue, and then centrifuged at 800 g and 4°C for 5 minutes to obtain spleen cells. The spleen cells were washed three times with cold 0.01 M PBS, and finally relative antibodies (respectively: CD45-FITC, CD3-APC, B220-PE-Cy7, CD3-APC, CD11c-APC and CD11b-PE-Cy7) were added to the spleen cells and incubated in the dark for 20 minutes. After the incubation, wash the cells three times and resuspend them in 100 μL 0.01M PBS. Add 1.0 μL DAPI (1 mg / mL) to the above solution and incubate for 10 min. After the incubation, the cells can be tested on the instrument. Fig. 9 The results showed that DCs and MΦ cells in the spleen of Ai9 mice treated with 18PA / DOPG / DOPS LNP appeared as tdTom+ cells, indicating that 18PA / DOPG / DOPS LNP were mainly transfected by antigen-presenting cells in the spleen.

[0137] Example 7: ELISA assay to detect OVA-specific antibodies in sera of immunized mice

[0138] 6-8 week old C57BL / 6 mice (18-20 g) were selected and inoculated with 18PA / DOPG / DOPS LNP preparations loaded with OVA mRNA (1.0 mg / kg OVA mRNA, 3 mice per group) through the tail vein on days 0 and 5. On the 14th day, 100 μL of blood was collected from the tail vein, and the collected whole blood was allowed to stand at 4°C for 30 min, and then centrifuged at 3000 rpm for 10 min in a pre-cooled centrifuge to collect serum, and the collected serum was placed at -20°C for use. The levels of antigen-specific IgG1 and IgG2c in the above serum were determined by ELISA. During the ELISA test, the OVA protein was dissolved in 50 mM carbonate buffer to a final concentration of 20 μg / mL, and then the above OVA protein solution was pre-coated in a 96-well plate (Nunc) and incubated overnight at 4°C. After incubation, the cells were washed three times with PBST (containing 0.05% tween-20, pH 7.4) and blocked for 1 h with PBST containing 10% FBS. After blocking, the cells were washed once with PBST. The serum collected from the immunized mice was diluted in series (from 2 7 Dilute to 2 21 ), then add the diluted serum to the well plate and incubate at 37°C for 2h. After the incubation, wash the well plate three times, add 100μL HRP-conjugated IgG1 and IgG2c antibodies (1:10000 dilution) and continue incubation under the same conditions for 1h. After the incubation, wash the well plate three times, add 100μL 3,3',5,5'-tetramethylbenzidine (TMB) substrate, incubate at 37°C for 5-10min, and then add 100μL stop solution. The optical density at a wavelength of 450nm was measured in an enzyme-linked immunosorbent assay. IgG1 antibodies are mainly induced by CD4+ helper T cells type 2 (Th2), while IgG2c antibodies are bound by CD4+ helper T cells type 1 (Th1). The above Fig.10 Results from A and 10B show that mice vaccinated with OVA mRNA preparations all produced high OVA-specific IgG1 titer responses. It is also worth noting that 18PA LNP did not show a significant IgG2c response, while DOPG / DOPS LNP produced a higher IgG2c response, indicating that DOPG / DOPS LNP can induce both Th1 and Th2 responses.

[0139] Example 8: In vivo OVA-specific CD8+ T cell detection

[0140] On day 0 and day 5, 6-8 week old C57BL / 6 mice were inoculated with 18PA / DOPG / DOPS LNP preparation loaded with OVA mRNA (1.5 mg / kg OVA mRNA, 4 mice per group) via the tail vein. On day 10, the immunized mice were euthanized, and spleen cells were collected according to the method described in Example 6. The spleen cells collected were then labeled by incubation with T-Select H-2KbOVA Tetramer-SIINFEKL-PE fluorescent antibody for 20 min in the dark. After washing the cells three times with 0.01 M PBS, CD8-FITC was added again and incubated at 4 ° C for 20 min. After washing the cells three times with 0.01 M PBS, the expression of OVA-specific CD8+T was analyzed by flow cytometry. For specific flow cytometric profiles, see Fig.11 A, combined with the above Fig.11 B The results show that 18PA / DOPG / DOPS LNP all significantly promoted the proliferation of OVA-specific CD8+T cells, among which DOPS LNP induced more OVA-specific CD8+T cells than 18PA / DOPG LNP.

[0141] Example 9: In vivo cytotoxic killing assay

[0142] On days 0 and 5, C57BL / 6 mice (6-8 weeks old) were inoculated with 18PA / DOPG / DOPS LNP formulations loaded with OVA mRNA (0.75 mg / kg OVA mRNA, 4 mice per group) through the tail vein. Nine days later, untreated (unimmunized) mice were euthanized, and spleen cells were collected according to the method described in Example 6, and the collected spleen cells were counted, and then the spleen cells were incubated with 10 μM OVA257-263 short peptide in complete medium at 37°C for 2 hours. After the incubation, the cells without peptide pulse and the cells with peptide pulse were incubated with 0.05 and 0.5 μM carboxyfluorescein succinimidyl ester (CFSE) in complete medium for 15 minutes, respectively. After the incubation, an equal number (1.5×10 7 0.05 μM CFSE-labeled cells without OVA peptide pulse and 0.5 μM CFSE-labeled cells with OVA peptide pulse were mixed and injected into the immunized mice through the tail vein. After 18 h, the spleen cells of the immunized mice were collected for flow cytometry analysis ( Fig.12 A). The percentage of specific killing of target cells pulsed with OVA peptide was calculated according to the following equation: Percentage of specific lysis = (1-experimental positive rate / non-transfer control positive rate) × 100%. For specific flow cytometry profiles, see Fig.12 B. Combining the above Fig.12 From the results of B and 12C, it can be seen that DOPG / DOPS LNP significantly increased the percentage of OVA-specific killing, while 18PA LNP only slightly increased the OVA-specific killing efficiency compared with the PBS group. It is also worth noting that DOPS LNP has a higher OVA-specific killing efficiency than DOPG LNP.

[0143] Example 10: Preparation and characterization of different Mn@mRNA-LNP formulations

[0144] Combined with the results of Examples 7 to 9, it was shown that DOPS LNP can induce Th1 and Th2 responses simultaneously, and can more efficiently induce antigen-specific T cell responses. Therefore, DOPS LNP was selected as the optimal dosage form, and subsequent experiments were all based on the preparation of Mn@mRNA-LNP by encapsulating manganese adjuvant in DOPS LNP dosage form.

[0145] ALC-0315, DSPC, cholesterol, DMG-PEG and DOPS were mixed at specific molar percentages (39.35:7.99:36.99:1.36:15.00), wherein ALC-0315, DSPC, cholesterol and DMG-PEG can be directly dissolved in ethanol, while the anionic lipid DOPS needs to be completely dissolved in anhydrous tetrahydrofuran before adding ethanol, so that the volume ratio of tetrahydrofuran to ethanol in the final DOPS anionic lipid solution is 2:1. MnCl with different mass ratios to DOPS was added. 2 The solution and mRNA were dissolved in 10 mM citrate buffer (pH 4.0), and then Mn@mRNA-LNPs were prepared as described in Example 2. The size, polydispersity index and zeta potential of the obtained adjuvant Mn with different mass were examined by DLS. 2+ Mn@mRNA-LNP(DOPS / Mn 2+ ,w / w), see Fig.13 A to Fig.13 B, The particle size and polydispersity index of all Mn@mRNA-LNP preparations did not change significantly. Fig.13 The zeta potential of all Mn@mRNA-LNP preparations is shown in C, showing that the zeta potential increases with the increase of Mn 2+ However, all Mn@mRNA-LNP preparations still carried negative charges. 2+The incorporation of Mn did not significantly affect the physicochemical properties of DOPS LNP. The mRNA and adjuvant Mn of all Mn@mRNA-LNP preparations were then determined by Ribogreen method and inductively coupled plasma-mass spectrometry (ICP-MS). 2+ The encapsulation efficiency (EE) is shown in Figure 14A. As Mn 2+ As the concentration of adjuvant increases, the mRNA encapsulation efficiency decreases. 2+ When the mass ratio was 1:1 and 1:2, there was no significant effect on the mRNA encapsulation efficiency. At the same time, the results of ICP-MS showed that ( Fig.14 B), all Mn@mRNA-LNP preparations can effectively encapsulate Mn 2+ Adjuvant, when DOPS and adjuvant Mn 2+ When the mass ratio is 1:1, Mn 2+ The optimal encapsulation efficiency can reach 65.97%.

[0146] Example 11: Delivery of different metal ion adjuvants by DOPS LNP delivery system

[0147] DOPS LNPs were prepared as shown in the preparation method of Example 10, and different metal ion adjuvants (CuCl 2 、ZnCl 2 or AlCl 3 ) and mRNA were dissolved in 10 mM citrate buffer (pH 4.0), and then LNPs were prepared as described in Example 2. The encapsulation efficiency of different metal ions was then detected by inductively coupled plasma-mass spectroscopy (ICP-MS). Fig.15 As shown, the DOPSLNP delivery system can effectively encapsulate Cu 2+ 、Zn 2+ and Al 3+ The packaging efficiencies were 28.55%, 51.94% and 51.32% respectively.

[0148] Example 12: Evaluation of transfection efficiency of different Mn@mRNA-LNP formulations

[0149] A549 cells (human non-small cell lung cancer cell line) were cultured at 0.8×10 4 The cells were inoculated at a density of 100 cells / mL in a 96-well plate, and then 50 μL of the adjuvant Mn obtained in Example 10 containing different masses was added.2+ The Mn@mRNA-LNP preparation was fixed with 0.2 μg Luc-mRNA in each well. The cell activity was then detected by the CCK-8 method and the expression of luciferase was detected as described in Example 4. The results are shown in Fig.16 As shown in A, all Mn@mRNA-LNP preparations were compared with the unencapsulated Mn 2+ Compared with the Mn@Luc-mRNA-LNP preparation, the cell survival rate was still around 80%, indicating that Mn 2+ The incorporation of Mn@Luc-mRNA-LNP did not increase the cytotoxicity of the LNP formulations, and all Mn@Luc-mRNA-LNP formulations had good biocompatibility. 2+ When the concentration of DOPS and Mn was gradually increased, the transfection efficiency of Mn@Luc-mRNA-LNP showed a trend of first increasing and then decreasing. 2+ When the mass ratio was 1:1, the transfection efficiency of the preparation reached its peak ( Fig.16 B).

[0150] Example 13: Evaluation of spleen targeting efficiency of different Mn@mRNA-LNP formulations

[0151] The adjuvant Mn prepared in Example 10 containing different masses 2+ Mn@mRNA-LNP(DOPS / Mn 2+ , w / w), and then, according to the mRNA encapsulation efficiency measured in Example 10, the mRNA dosage (0.1 mg / kg Luc mRNA) was unified, and the fluorescence intensity of the main organs of the mice treated with the above preparations was analyzed as described in Example 3. The results are shown in Fig.17 As shown in A and 17B, all Mn@Luc-mRNA-LNP formulations were compared with those without adjuvant Mn 2+ Compared with the Mn@mRNA-LNP preparation, the fluorescence intensity in the spleen was comparable, and the spleen targeting efficiency did not change significantly ( Fig.18 ), indicating that the adjuvant Mn 2+ The incorporation of did not affect the expression efficiency of Luc-mRNA in the spleen and the spleen targeting efficiency.

[0152] Example 14: Evaluation of the ability of different Mn@mRNA-LNP formulations to promote dendritic cell maturation

[0153] The adjuvant Mn prepared in Example 10 containing different masses 2+ Mn@OVA-mRNA-LNP(DOPS / Mn 2+, w / w), incubated with immature BMDCs at 37°C for 48 hours as described in Example 5, the cells were collected and labeled with CD11c-APC and CD-86-PE-Cy7 in the dark for 20 minutes, washed three times with 0.01M PBS, and analyzed by flow cytometry for the expression of CD11c+CD86+ on BMDCs. For specific flow cytometric profiles, see Fig.19 A. Combining the above Fig.19 A and 19B results show that, compared with the unencapsulated adjuvant Mn 2+ Compared with the Mn@OVA-mRNA-LNP formulations, all the adjuvant Mn 2+ The Mn@OVA-mRNA-LNP formulations significantly increased the expression of CD86. It is also worth noting that only a small amount of adjuvant Mn 2+ (DOPS / Mn 2+ ,w / w,1:1) can further promote the maturation of BMDCs.

[0154] Example 15: In vitro evaluation of IRF-7 and IFN-β gene expression by RT-PCR

[0155] Based on the results of Example 10 and Examples 12 to 14, it is shown that Mn@mRNA-LNP (DOPS / Mn 2+ ,w / w,1:1) can further efficiently encapsulate the adjuvant Mn without affecting mRNA encapsulation 2+ , and this formulation showed good transfection efficiency, spleen targeting efficiency and ability to promote BMDCs maturation, so it was selected as the best formulation for subsequent experiments. First, in this example, the ability of Mn@OVA-mRNA-LNP to activate the STING signaling pathway was evaluated, and the expression of IRF-7 and IFN-β genes in the STING signaling pathway was detected by RT-PCR experiments. Therefore, 2×10 5 DC2.4 cells were incubated at 37°C for 24 hours. 2 (abbreviated as Mn), DOPS LNP (abbreviated as DOPS), DOPS LNP+MnCl 2 (abbreviated as DOPS+Mn, indicating MnCl 2 Instead of loading DOPS LNP by encapsulation, DOPS LNP and MnCl 2Mix well) and Mn@OVA-mRNA-LNP were incubated with cells for 8 h or 24 h. After incubation, cells were collected and total mRNA was isolated using RNA isolater Total RNA Extraction Reagent (Vazyme) according to the manufacturer's manual. Complementary DNA (cDNA) was synthesized using a high-capacity cDNA reverse transcription kit (Vazyme). RT-PCR was performed using ChamQ Universal SYBR qPCR Master Mix (Vazyme) and Detection was performed using the 96 fluorescence quantitative PCR detection system. Relative gene expression was analyzed using 96SW 1.1 software. Fig. 20 As shown in A and 20B, the Mn@OVA-mRNA-LNP group could upregulate the expression of IRF-7 and IFN-β mRNA at the early time point of 8 h, and after 24 h, Mn@OVA-mRNA-LNP could induce a higher response compared with the other groups.

[0156] Example 16: Experiment on the activation of dendritic cells promoted by Mn@mRNA-LNP

[0157] As described in Example 5, immature BMDCs were incubated with the groups described in Example 15 at 37°C for 48 hours (LPS was used as a positive reference group), and the cells were collected and labeled with CD11c-APC, CD-86-PE-Cy7, and MHC II-FITC in the dark for 20 minutes. After washing the cells three times with 0.01M PBS, the expression of CD11c+CD86+ and CD11c+CD40+ on BMDCs was analyzed by flow cytometry. Fig.21 The results of A and 21B show that after immature BMDCs were co-incubated with Mn@OVA-mRNA-LNP for 48 hours, the expression of BMDC activation markers (CD86 and CD40) in the Mn@OVA-mRNA-LNP group was significantly increased compared with the Mn group, DOPS group and DOPS+Mn group.

[0158] Example 17: Evaluation of T cell responses stimulated by Mn@mRNA-LNP in the spleen

[0159] 6-8 week old C57BL / 6 mice were selected and divided into five groups as described in Example 15. Different OVA mRNA preparations were inoculated into the mice through the tail vein on day 0 and day 5, respectively. The immunized mice were euthanized on day 10, and spleen cells were collected according to the method described in Example 6. Finally, the secretion of CD8+IFN-γ+T and the expression of OVA-specific T cells in the spleen after vaccination were analyzed by flow cytometry. Regarding the detection of CD8+IFN-γ+T, the collected spleen cells were labeled by incubating with CD8-FITC for 20 minutes in the dark. After washing the cells three times with 0.01M PBS, the cells were resuspended with 200μL pre-cooled Fixation / permeabilization solution and incubated at 4°C for 30 minutes. After the incubation, the cells were collected by centrifugation at 1000g for 5 minutes, and then diluted to 1×BD perm / Wash TM The cells were washed twice, and IFN-γ-PE-Cy7 flow cytometry antibody was added to the cells, and incubated again for 20 min under the same conditions. The detection method of OVA-specific T cells is as described in Example 8. For specific flow cytometry maps, see Fig. 22 A, combined with the above Fig. 22 The results of B and 22C showed that the Mn@OVA-mRNA-LNP group further promoted the secretion of the proinflammatory cytokine IFN-γ and the proliferation of OVA-specific T cells compared with the other groups, indicating that the Mn@OVA-mRNA-LNP group can more effectively activate T cell responses in the spleen and induce the proliferation of specific T cells.

[0160] Subsequently, the in vivo cytotoxic killing ability of Mn@OVA-mRNA-LNP was further evaluated. 6-8 week old C57BL / 6 mice were divided into five groups as described in Example 15, and the detection method was as described in Example 9. For specific flow cytometry profiles, see Fig.23 A, the results are as follows Fig.23 As shown in B, both the Mn group and the PBS group failed to induce OVA-specific killing. The DOPS group was similar to the DOPS+Mn group, both showing a high OVA-specific killing efficiency. The OVA-specific killing efficiency of Mn@OVA-mRNA-LNP was 62.28±7.64%, which was significantly higher than that of NC (10.50±4.95%), Mn group (16.84±12.05%), DOPS group (47.37±4.74%) and DOPS+Mn group (44.53±7.28%), indicating that the Mn@OVA-mRNA-LNP group can induce a higher cytotoxic T lymphocyte response (CTL).

[0161] Example 18: Evaluation of the anti-tumor and immune efficacy of Mn@mRNA-LNP

[0162] Select 22-25g immune-competent C57BL / 6 mice (6-8 weeks old) and place 1.5×10 5 B16-OVA cells cultured under standard conditions were inoculated subcutaneously in the right groin of mice. 3 The mice were divided into PBS group, Mn group, DOPS group, DOPS+Mn group and Mn@OVA-mRNA-LNP group according to the grouping method of Example 15. The different OVA mRNA preparations (2.0 mg / kg OVA mRNA, 8 mice in each group) were inoculated through the tail vein of mice every four days for a total of 2 times, 200 μL per mouse, wherein PBS was 0.01 M PBS, and the adjuvant Mn in the Mn and DOPS+Mn groups was 1.5 mg / kg OVA mRNA, 2.0 mg / kg OVA mRNA, 8 mice in each group, 2 times in total, 200 μL per mouse, 2+ The dosage of adjuvant Mn can be determined based on the 2.0 mg / kg OVA mRNA dosage measured in Example 10. 2+ The encapsulation efficiency was calculated to be ( Fig.24 A). After the administration, the growth of mice was continuously observed, the size of tumors was measured every other day, the weight of tumor-bearing mice was weighed, and the tumor volume and survival curve of mice were calculated. Tumor volume (V) = (the longest diameter of tumor (mm) × the shortest diameter of tumor (mm) 2 ) / 2, and the survival time is from the time of tumor inoculation to the death of the mouse or the tumor volume exceeds the animal ethics regulations of this unit (>1500mm 3 ) time interval. The result is as follows Fig.24 As shown in B, the tumors in the PBS group and the Mn group grew rapidly and could not inhibit the progression of the tumor. The DOPS group and the DOPS+Mn group could effectively delay the growth of the tumor, but ultimately could not inhibit the growth of the tumor. The Mn@OVA-mRNA-LNP group significantly inhibited the growth of the tumor compared with the other groups and effectively prolonged the survival period of the mice ( Fig.25 ).

[0163] The anti-tumor immune response of Mn@mRNA-LNP was evaluated by analyzing the infiltration of CD4+ / CD8+T cells in tumor tissue sections of each group using tissue multi-channel / multi-color immunofluorescence. Fig.26As shown, the fluorescence signals of CD4+T (red fluorescence) and CD8+T (green fluorescence) cells in the PBS group and the Mn group were less, indicating that the infiltration of T cells in their tumors was less. The fluorescence signals of CD4+T and CD8+T cells increased in the DOPS group and the DOPS+Mn group, and the fluorescence signals of CD4+T and CD8+T cells were obviously observed in the Mn@OVA-mRNA-LNP group, indicating that the Mn@OVA-mRNA-LNP group effectively induced T cell responses and promoted the infiltration of effector T cells in the tumor site compared with other groups. Subsequently, the tumor tissues of mice in each group (four mice in each group) were collected after 22 days of treatment, and the tumor tissues were placed in complete culture medium. Under sterile conditions, the tumor tissues were fully minced, and enzyme digestion solution containing 0.2 mg / mL DNAse I and hyaluronidase and 1 mg / mL type IV collagenase was added, and digestion was carried out at 37°C for 1-2 hours. After the culture medium became turbid, RPMI-1640 culture medium containing 10% FBS was added to terminate the digestion. The single cell suspension of the above tumor tissue was passed through a 40 μm sieve to remove undigested large pieces of tissue, centrifuged at 800 g for 5 min at 4°C, and washed three times with 0.01 M PBS buffer to obtain a single cell suspension of tumor tissue. The above cells were labeled by incubating with CD45-PE-Cy7, CD3-APC, and CD8-FITC in the dark for 20 min, washed three times with 0.01 M PBS, and analyzed by flow cytometry for the proportion of CD8+ T cells infiltrating the tumor. Fig. 27 As shown in the figure, the percentages of CD45+CD3+ and CD45+CD3+CD8+ T cells in the tumor in the Mn@OVA-mRNA-LNP group increased by 3.84 and 4.54 times, respectively, compared with those in PBS, indicating that Mn@OVA-mRNA-LNP effectively increased the infiltration of cytotoxic T lymphocytes (CTLs), further stimulating the anti-tumor immune response, thereby inhibiting or even killing the tumor.

[0164] At present, surgery is still the preferred treatment option for cancer in clinical practice. However, despite the continuous development of diagnostic and treatment methods, postoperative tumor recurrence and metastasis are still the main cause of death in cancer patients. Therefore, we constructed a mouse tumor postoperative recurrence model to evaluate the inhibitory effect of Mn@OVA-mRNA-LNP on postoperative recurrent tumors. 6-8 week old C57BL / 6 mice were randomly divided into 2 groups (PBS group and Mn@OVA-mRNA-LNP group). On day 0, 1.5×10 5 B16-OVA cells cultured under standard conditions. When the tumor grows to about 500 mm 3, 99% of the tumor was surgically removed, and 1% of the tumor remained. The wound was then sutured with a wound clip to simulate tumor recurrence after surgery (day 19). Mn@OVA-mRNA-LNP preparations were inoculated through the tail vein of mice on days 22, 25, and 28 after surgery. After the administration, the growth of the mice was continuously observed, the tumor size of the mice was measured every other day, the weight of the tumor-bearing mice was weighed, and the tumor volume and survival curve of the mice were calculated ( Fig.28 A) The results are as follows Fig.28 B and 29 show that compared with the PBS group, the Mn@OVA-mRNA-LNP group effectively delayed the recurrence of tumors and significantly prolonged the survival period of mice after surgery. Subsequently, the mice in each group were anesthetized, and the whole blood of the mice in each group was collected with an anticoagulant tube containing sodium heparin. The collected whole blood was placed in a centrifuge precooled to 4°C and centrifuged at 8000g for 5 minutes, and then five times the volume of red blood cell lysis solution was added and fully mixed, and then stood for 5-10 minutes, and centrifuged at 800g for 5 minutes at 4°C, and washed three times with 0.01M PBS buffer to obtain peripheral blood T lymphocytes. The corresponding flow antibodies (CD3-APC, CD4-FITC, CD8-PE, CD44-PE-Cy7 and CD62L-PerCP-Cy5.5) were added to the above cells and incubated for 20 minutes under light-proof conditions. After incubation, the cells were washed twice with PBS buffer and resuspended with 200 μL PBS buffer. The secretion of memory T cells in the peripheral blood of postoperative mice was analyzed by flow cytometry. Fig.30 As shown in A to 30C, the Mn@OVA-mRNA-LNP group significantly increased the proportion of effector memory T cells in the peripheral blood compared with the PBS group, indicating that mice treated with Mn@OVA-mRNA-LNP had better anti-tumor immune memory.

[0165] Example 19: Neoantigen-specific T cell detection

[0166] In this example, seven MC38 (mouse colon cancer cell line) neoantigen sequences were screened (the expression of MC38 neoantigens is composed of CPNE1, IRGQ, AATF, RESP1, MED12, DPAGT1 and ADPGK genes, as shown in Table 2), and these sequences were synthesized into Neo-mRNA as shown in Example 1, and then the neoantigen-specific T cell response induced by Neo-mRNA in vivo was further detected. First, on days 0 and 5, 6-8 week old C57BL / 6 mice were inoculated with Neo-mRNA preparations (Mn@mRNA-LNP, 2.0 mg / kg Neo-mRNA) through the tail vein. On the 10th day, the above-mentioned immunized mice were euthanized, and the mouse spleen cells were extracted, and the obtained spleen cells were divided into two groups, A and B. Group A was in the above-mentioned spleen cells (2.0×106 BMDCs (2.0×10 5 BMDCs cells) were co-cultured for 48 h. Group B was directly cultured with the above spleen cells (2.0×10 6 ADPGK or RESP1 polypeptide (2.0 μg / mL) was added to each spleen cell) and incubated for 48 h. The peptide diluent dimethyl sulfoxide (DMSO) was used as a negative control. Then, cells from groups A and B were collected and the secretion of CD8+IFN-γ+T cells was analyzed as described in Example 17. For specific flow cytometry profiles, see Fig.31 A, combined with the above Fig.31 From the results of B and 31C, it can be seen that the secretion of CD8+IFN-γ+T was significantly increased after the T cells extracted after vaccination with Neo-mRNA preparations were stimulated again with ADPGK or RESP1 neoantigen peptides or BMDCs incubated with ADPGK or RESP1 neoantigen peptides, proving that Neo-mRNA preparations can induce the production of neoantigen-specific T cells and activate specific T cell immune responses.

[0167] Subsequently, the in vivo cytotoxic killing ability of the Neo-mRNA preparation was further evaluated. C57BL / 6 mice aged 6-8 weeks were divided into three groups: PBS group, Mn@Luc-mRNA-LNP group and Mn@Neo-mRNA-LNP group. The detection method was the same as that described in Example 9, except that 20 μM ADPGK or RESP1 polypeptide was used to pulse the spleen cells. For specific flow cytometry profiles, see Fig.32 A, the results are as follows Fig.32 As shown in Figures B and 32C, both the Mn@Luc-mRNA-LNP group and the PBS group failed to induce ADPGK / RESP1-specific killing, while the ADPGK-specific killing efficiency of Mn@Neo-mRNA-LNP was 45.41±15.06% and the RESP1-specific killing efficiency was 32.42±5.02%, which were significantly higher than those of the PBS group and the Mn@Luc-mRNA-LNP group, indicating that the Mn@Neo-mRNA-LNP group can activate neoantigen-specific T cell responses and induce higher CTL responses.

[0168] Table 2: Seven amino acid sequences of MC38 neoantigens encoded by Neo-mRNA

[0169]

[0170] Example 20: Evaluation of the anti-tumor efficacy of Mn@Neo-mRNA-LNP

[0171] Select 22-25g immune-competent C57BL / 6 mice and place 2.0×10 5 MC38 cells cultured under standard conditions were inoculated subcutaneously in the right groin of mice. 3 The mice were divided into PBS group, anti-PD-1 group, Mn@Neo-mRNA-LNP group and Mn@Neo-mRNA-LNP+anti-PD-1 group (8 mice in each group). Mn@Neo-mRNA-LNP preparation (2.0 mg / kg Neo mRNA) and anti-PD-1 antibody (2.5 mg / kg) were injected intraperitoneally through the tail vein of mice on days 10, 13, 17 and 20, respectively, for a total of 4 times ( Fig.33 A). After the administration, the growth of mice was continuously observed, the size of tumors was measured every other day, the weight of tumor-bearing mice was weighed, and the tumor volume and survival curve of mice were calculated. Fig.33 As shown in B, the tumor in the PBS group progressed faster, and the complete tumor inhibition rate was 0.0%. At the same time, the anti-PD-1 group and the Mn@Neo-mRNA-LNP group could effectively delay the growth of the tumor, but the complete tumor inhibition rate was only 0.0%, while the Mn@Neo-mRNA-LNP combined with anti-PD-1 antibody significantly inhibited the growth of the tumor, with a complete tumor inhibition rate of 25.0%. At the same time, the Mn@Neo-mRNA-LNP combined with anti-PD-1 antibody group effectively prolonged the survival period of mice compared with the PBS group, anti-PD-1 group and Mn@Neo-mRNA-LNP group ( Fig.34 ). This indicates that the combination of Mn@Neo-mRNA-LNP and therapeutic PD-1 antibody further improved the anti-tumor efficacy of Mn@Neo-mRNA-LNP.

[0172] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. A spleen-targeted lipid nanoparticle encapsulating mRNA, comprising a spleen-targeted lipid nanoparticle and mRNA; the spleen-targeted lipid nanoparticle, the raw materials of which include ionizable lipids, auxiliary phospholipids, steroidal lipids, polyethylene glycol-lipid conjugates and targeting functional lipids; in, The targeted functional lipid is an anionic lipid, and the anionic lipid is selected from phospholipids containing at least one of the following anionic heads: phosphatidylglycerol (PG), phosphatidylserine (PS) and phosphatidic acid (PA).

2. The spleen-targeted lipid nanoparticles containing mRNA according to claim 1, Features: The molar percentage of the anionic lipid to the total lipid of the raw material is 1-50%, preferably 5-30%, more preferably 10-20%, and more preferably 15%.

3. The spleen-targeted lipid nanoparticles containing mRNA according to claim 1 or 2, Features: The ionizable lipid is selected from at least one of the following: SM-102 (heptadecan-9-yl-8-((2-hydroxyethyl)(6-oxo-6-((undecanyloxy)hexyl)aminocaprylate)), ALC-0315 (((4-hydroxybutyl)azepinediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)), cKK-E12 (3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione), DLin -MC3-DMA (4-(N,N-dimethylamino)butyric acid (dilinoleyl) methyl ester), DLin-KC2-DMA (N,N-dimethyl-2,2-di-(9Z,12Z)-9,12-octadecen-1-yl-1,3-dioxolane-4-ethylamine) and 306Oi10 (tetrakis(8-methylnonyl) 3,3',3",3"'-(((methylazadialkyl)bis(propane-3,1-diyl))bis(azatriyl))tetrapropionate); And / or, the auxiliary phospholipid is selected from at least one of the following: DSPC (1,2-distearoyl-sn-glyceryl-3-phosphatidylcholine), DPPC (1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylcholine), DOPC (1,2-dioleoyl-sn-glyceryl-3-phosphatidylcholine), POPC (2-oleoyl-1-palmitoyl-sn-glyceryl-3-phosphatidylcholine), DOPE (1,2-dioleoyl-sn-glyceryl-3-phosphatidylethanolamine), POPE (1-palmitoyl-2-oleoyl-phosphatidylethanolamine), DSPE (1,2-distearoyl-sn-glyceryl-3-phosphatidylethanolamine) and DPPE (1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylethanolamine); and / or, the steroidal lipid is selected from at least one of the following: cholesterol, cholestanol, 7α-hydroxycholesterol, β-sitosterol, 7β-hydroxycholesterol, cholestanone and cholestenone; And / or, the polyethylene glycol-lipid conjugate is selected from at least one of the following: DMG-PEG2000 (1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000), DSG-PEG2000 (1,2-distearoyl-rac-glycerol-3-methoxypolyethylene glycol 2000), DSPE-mPEG2000 (distearoylphosphatidyl acetamide-methoxypolyethylene glycol 2000) and ALC-0159 (methoxypolyethylene glycol ditetradecyl acetamide); And / or, the phospholipid containing a phosphatidylglycerol (PG) anion head is selected from at least one of the following: DMPG (1,2-dimyristoyl-sn-glyceryl-3-phospho-RAC-(1-glycerol) sodium salt), DOPG (1,2-dioleoyl-sn-glyceryl-3-phospho-RAC-glycerol sodium salt), DSPG (1,2-distearoyl-tin-glycerol-3-phospho-rac-(1-glycerol) sodium salt), DLPG (1,2-dilauroyl-sn-glycerol-3-phospho-(1'-rac-glycerol) sodium salt), DPPG (1,2-dipalmitoyl-sn-glycerol-3-phospho-(1'-rac-glycerol) sodium salt), POPG (1-palmitoyl-2-oleyl-sn-glycerol-3-phospho-rac-(1-glycerol) sodium salt) one or more; And / or, the phospholipid containing a phosphatidylserine (PS) anion head is selected from at least one of the following: DOPS (1,2-dioleoyl-sn-glycerol-3-phospho-L-serine sodium salt), DSPS (1,2-distearoyl-sn-glycerol-3-phospho-L-serine sodium salt), 16:0-18:2PS (1-palmitoyl-2-linoleoyl-sn-glycerol-3-phospho-L-serine sodium salt), 18:0-18:1PS (1-stearoyl-2-oleoyl-sn-glycerol-3-phospho-L-serine sodium salt), 18:0-18:2PS (1-stearoyl-2-linoleoyl-sn-glycerol-3-phospho-L-serine sodium salt) and POPS (1-palmitoyl-2-oleoyl-sn-glycerol-3-phospho-L-serine sodium salt) One or more; And / or, the phospholipid containing a phosphatidic acid (PA) anion head is selected from at least one of the following: 17:0PA (1,2-heptadecanoyl-sn-glycerol-3-phosphate sodium salt), 18PA (1,2-dioleoyl-sn-glycerol-3-phosphate sodium salt), DMPA (1,2-dimyristoyl-sn-glycerol-3-phosphate sodium salt), DLPA (1,2-dilauroyl-sn-glycerol-3-phosphate sodium salt), DSPA (1,2-distearoyl-sn-glycerol-3-phosphate sodium salt), POPA (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate sodium salt) or more; And / or, the mRNA is any mRNA molecule that can encode one or more tumor antigens.

4. The spleen-targeted lipid nanoparticles containing mRNA according to any one of claims 1 to 3, Features: The molar percentage of the ionizable lipids to the total lipids of the raw material is 20-60%, preferably 30-50%, and more preferably 39.35%; And / or, the molar percentage of the auxiliary phospholipids to the total lipids of the raw material is 1-20%, preferably 2-10%, more preferably 7.99%; and / or, the molar percentage of the steroidal lipids in the total lipids of the raw material is 20-60%, preferably 30-50%, more preferably 36.29%; and / or, the molar percentage of the polyethylene glycol-lipid conjugate is 0.1-10%, preferably 0.5-5%, more preferably 1.36%; And / or, the mass ratio of the total mass of lipid molecules forming the spleen-targeted lipid nanoparticles to the nucleic acid in the spleen-targeted lipid nanoparticles encapsulating mRNA is (10-50):

1.

5. A method for preparing the spleen-targeted lipid nanoparticles encapsulating mRNA according to any one of claims 1 to 4, comprising the following steps: Step (A1): dissolving an ionizable cationic lipid, an auxiliary phospholipid, a steroidal lipid, a polyethylene glycol-lipid conjugate and a targeting functional lipid in an organic solvent at a specific molar percentage to obtain a lipid organic phase; Step (A2): dissolving the mRNA in an appropriate buffer solution to obtain an mRNA solution; Step (A3): The lipid organic phase in step (A1) and the mRNA solution in step (A2) are mixed and incubated to obtain a solution of spleen-targeted lipid nanoparticles encapsulating mRNA.

6. The preparation method according to claim 5, Features: The organic solvent includes any one of methanol, ethanol, propanol, tetrahydrofuran, and ether, or a combination of at least two thereof; And / or, the pH value of the buffer solution is 2.0-8.0, preferably the pH value is 4.0; And / or, the mass ratio of the total mass of lipid molecules in the lipid organic phase to the mass ratio of mRNA in the mRNA solution is (10-50):1, and the preferred mass ratio is 40:1; And / or, the volume ratio of the lipid organic phase to the mRNA solution is 1:(1-5), preferably 1:3; And / or, the incubation condition is static incubation at room temperature for 10-15 minutes.

7. A spleen-targeted lipid nanoparticle encapsulating mRNA and adjuvant metal ions, comprising the spleen-targeted lipid nanoparticle encapsulating mRNA as described in any one of claims 1-4 and adjuvant metal ions.

8. The spleen-targeted lipid nanoparticles containing mRNA and adjuvant metal ions according to claim 7, Features: The metal ions include but are not limited to one or more of manganese ions, copper ions, zinc ions, aluminum ions, iron ions, ferrous ions, and cobalt ions, preferably manganese ions; And / or, the metal ion is a manganese ion, and the mass ratio of the anionic lipid to the manganese ion in the spleen-targeted lipid nanoparticles encapsulating mRNA is 1:(0-10), preferably 1:(1-5), and most preferably 1:1; And / or, the adjuvant manganese ion is a divalent manganese salt including any one of manganese chloride, manganese nitrate and manganese sulfate, preferably manganese chloride.

9. The method for preparing the spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions according to claim 7 or 8, comprising the following steps: Step (B1): dissolving ionizable cationic lipids, auxiliary phospholipids, steroidal lipids, polyethylene glycol-lipid conjugates and targeted functional lipids in an organic solvent at a specific molar percentage to obtain a lipid organic phase; Step (B2): dissolving the adjuvant metal ion and mRNA with an appropriate buffer solution to obtain an aqueous solution; Step (B3): The lipid organic phase in step (B1) and the aqueous phase solution in step (B2) are mixed and incubated to obtain a solution of spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions.

10. The preparation method according to claim 9, Features: The organic solvent includes any one of methanol, ethanol, propanol, tetrahydrofuran, and ether, or a combination of at least two thereof; And / or, the pH value of the buffer solution is 2.0-8.0, preferably the pH value is 4.0; And / or, the mass ratio of anionic lipid to adjuvant metal ion in the lipid organic phase is 1:(0-10), preferably 1:(1-5), and most preferably 1:1; And / or, the mass ratio of the total mass of lipid molecules in the lipid organic phase to the mass ratio of mRNA in the mRNA solution is (10-50):1, and the preferred mass ratio is 40:1; And / or, the volume ratio of the lipid organic phase to the mRNA solution is 1:(1-5), preferably 1:3; And / or, the incubation condition is static incubation at room temperature for 10-15 minutes.

11. Use of the spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions according to claim 7 or 8 in preparing a vaccine for tumor immunotherapy; Preferably, the tumor includes but is not limited to one or more of melanoma, colon cancer, liver cancer, breast cancer, glioma, ovarian cancer, gastric cancer, prostate cancer and lung cancer.

12. A pharmaceutical composition for treating tumors, comprising the spleen-targeted lipid nanoparticles encapsulating mRNA and adjuvant metal ions as described in claim 7 or 8, and an immune checkpoint inhibitor.

13. A method for treating a tumor, comprising administering the pharmaceutical composition for treating a tumor according to claim 12 to a subject in need thereof.

Citation Information

Patent Citations

  • Lipid nanoparticle as well as preparation method and application thereof

    CN116763756A

  • Mn &lt; 2 + &gt;-loaded lipid nanoparticles as well as preparation method and application thereof

    CN118178682A

  • Ionizable cationic lipids

    US20220162521A1

  • Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same

    WO2023190176A1

Cited By

  • Preparation method of arachidonic acid lipid nano drug delivery system

    CN121401237A

  • Preparation method of arachidonic acid lipid nano drug delivery system

    CN121401237B

  • Manganese dioxide nano vaccine for dendritic cell targeted delivery of tumor neoantigen as well as preparation method and application of manganese dioxide nano vaccine

    CN122140910A